Individual scientists attached to research institutions and domestic companies like Lupin, Dr Reddy's and Cadila account for the rest.
Drug banks, cancer fund now health ministry's babies.
Indian companies are unable to raise prices because 35 per cent of the drugs sold in the country come under the government's price control order.
With financial results for the quarter round the corner, small- and medium-sized, export-oriented pharmaceutical companies are expecting a 5-10 per cent decline in their bottom line for the April-June period, owing to the rupee appreciation.
Another user of the data is the clinical diabetics' consortium, which aims to identify if there are specific genetic reasons for a particular ethnic group to be predisposed to the disease.
The move is in line with the NPPA's recent policy of putting a cap on prices.
The hospital has ordered a new cath-lab and is readying its entire idle capacities to make room for Trehan's surgeons.
In April, Mumbai-based pharmaceutical company Wockhardt announced it had received five marketing approvals for its generic medicines, versions of those that have gone off patents, from the US Food and Drug Administration in five weeks.
Ranbaxy earned $114 million from its US operations in 2006. It launched 10 new products during the year. The company said that the revenues from the sale of the newly acquired brands would be reflected from the next quarter.
Shivinder's dream project, of course, is the Medicity he wants to put up at Gurgaon on the outskirts of New Delhi. That is where the problem with Trehan began, who has his own plans to come up with a similar project at Gurgaon.
Following hectic negotiations, Fortis Healthcare managing director Shivinder Singh and Naresh Trehan have finally smoked the peace pipe
After making big-ticket acquisitions abroad, leading Indian pharmaceutical companies like Dr Reddy's Laboratories, Ranbaxy Laboratories, and Aurobindo Pharma are rapidly shifting production to their Indian facilities.
With India slowly but steadily morphing into a global pharmaceutical R&D hub, scientists have run into short supply.
The changes would be immediately effective in countries like Columbia, South Korea, Peru and Panama, where FTAs are in the final stages of approval.
In a landmark judgment likely to benefit Indian generic drug manufacturers in a big way, the US Supreme Court has ruled against patenting of products with slight modifications.
The contract research and manufacturing services may soon replace generic drugs manufacturing as the preferred business option for Indian pharmaceutical industry, if growing revenues from CRAMS business is any indication.
Ranbaxy Laboratories, the country's biggest drugmaker, is all set to focus its energies in developing and marketing niche products where price erosion is minimal
The pace of privatisation of the Indian healthcare segment is expected to be the fastest in the coming years.
Over 30 domestic pharmaceutical companies, including Ranbaxy, Cipla, Nicholas Piramal, Zydus Cadila and Torrent, face a possible ban on the sale of the generic version of Merck's pain management drug in the Indian market.
Data from the Central Information Commission, the apex body that hears complaints regarding denial of information under RTI, shows that corporate houses are increasingly using RTI to extract information from public authorities.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances